<DOC>
	<DOC>NCT00156923</DOC>
	<brief_summary>This was a Phase 3, multi-center extension of Alkermes' Study ALK21-003EXT (NCT01218971) to further assess the long-term safety of repeat monthly doses of Medisorb速 naltrexone (VIVITROL速).</brief_summary>
	<brief_title>ALK21-010: Long-term Safety of Medisorb速 Naltrexone (VIVITROL速) in Alcohol-dependent Adults</brief_title>
	<detailed_description>Enrolled subjects continued to receive the same dose strength of Medisorb naltrexone (ie, 190 mg or 380 mg) they had received in Study ALK21-003-EXT (NCT01218971). Assigned dose strength (high or low) was not revealed to the subject, the study investigators, or any blinded member of the clinical study team for the duration of the study period. Placebo was not administered.</detailed_description>
	<mesh_term>Alcoholism</mesh_term>
	<mesh_term>Naltrexone</mesh_term>
	<criteria>Primary Completed Study ALK21003EXT (NCT01218971), receiving all 13 injections Willing and able to return for scheduled clinic visits and study assessments Noncustodial, stable address and phone Written, informed consent Primary Pregnancy or lactation Terminated early from study drug in Study ALK21003EXT (NCT01218971)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2010</verification_date>
	<keyword>Alcohol dependence</keyword>
</DOC>